Neuro-All December 2015

neuro-all@lists.umanitoba.ca

1 participants
5 discussions

MNN Speaker - Dr. Timothy Kennedy Friday, Jan 15, 2016 *3pm Theatre C

by Winnipeg Chapter Society for Neuroscience

Everyone is invited.... Manitoba Neuroscience Network 2015/2016 Seminar & Visiting Speaker Series Friday, January 15th, 2016 | 3:00 p.m. Timothy Kennedy <https://www.mcgill.ca/neuro/research/researchers/kennedy> Professor - Department of Neurology & Neurosurgery co-Director - McGill Program in NeuroEngineering Montreal Neurological Institute McGill University TOPIC: Making Connections: New Roles for Netrin-1 and DCC Regulating Myelination, Synaptogenesis, and Plasticity Location: Theatre C, Bannatyne Campus Visit Dr. Kennedy's Website to learn about his research: https://www.mcgill.ca/neuro/research/researchers/kennedy For more information, please contact the MNN Office at 204.235.3939 The 2015/2016 MNN Seminar & Visiting Speaker Series is funded by: * Winnipeg Chapter Society for Neuroscience - Manitoba Neuroscience Network * Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre * Neuroscience Research Program, Health Sciences Centre & University of Manitoba Kelly Jorundson Winnipeg Chapter Society for Neuroscience R4046 - 351 Tache Avenue Winnipeg, MB R2H 2A6 Tel: 204.235.3939 Fax: 204.237.4092 Email: kjorund(a)sbrc.ca OR kjorund(a)yahoo.ca Website: www.sfn-manitoba.ca

8 years, 4 months

Reminder: MNN Visiting Speaker - Friday Dec 11 @ **3pm - Theatre C Dr. Yu Tian Wang

by Winnipeg Chapter Society for Neuroscience

Everyone is invited to attend.... Manitoba Neuroscience Network 2015/2016 Seminar & Visiting Speaker Series Friday, December 11th, 2015 | 3:00 p.m. Yu Tian Wang <http://www.neuroscience.ubc.ca/people/Wang> Professor, Department of Medicine, Division of Neurology Chair in Stroke Research University of British Columbia TOPIC: Peptide-based research tools and therapeutics in the post-genome era Location: Theatre C, Bannatyne Campus Research Focus: I have a long-standing research interest in understanding the molecular mechanisms responsible for regulating the function and intracellular trafficking of neurotransmitter receptors critical for brain functions such as learning, memory and cognition, and investigating the manner by which these mechanisms may be altered in central nervous disease processes. My goal is to be able to treat central nervous disorders such as stroke, drug addiction, and schizophrenia by designing new therapeutics that specifically target these receptors and their pathways. With particular relevance to this project, we have made a significant impact on stroke research. We discovered that NMDA receptor NR2A and NR2B subunits have respective roles in promoting cell survival and cell death (J. Neurosci. 27:2846, 2007). We have characterized the molecular steps downstream of the NR2B death pathway, and also developed several specific inhibitors to disrupt this pathway and demonstrated their therapeutic potentials in reducing brain damage following stroke (Science 298:846, 2002; JBC 279:41267, 2004; Nature Med. 15:1399, 2009; J. Neurosci. 33:7997, 2013). To translate these basic scientific discoveries into potential therapeutics for brain dysfunctions, I founded, along with five other scientists/clinicians, the NoNO Inc. in Toronto that has recently completed a successful phase 2 clinical trial, demonstrating for the first time a clinically effective neuroprotectant NA-1 (Tat-NR2B9c) in reducing ischemic brain damage (Lancet Neurol 11:942, 2012). Our research expertise spans functionally characterizing synaptic plasticity, biochemically mapping protein-protein interaction sites, and designing specific peptides for use in models of CNS disorders. Kelly Jorundson Winnipeg Chapter Society for Neuroscience R4046 - 351 Tache Avenue Winnipeg, MB R2H 2A6 Tel: 204.235.3939 Fax: 204.237.4092 Email: kjorund(a)sbrc.ca OR kjorund(a)yahoo.ca Website: www.sfn-manitoba.ca

8 years, 4 months

Recall: Reminder: Friday - Dec 4th 9am - MNN Speaker - Dr. Chris Proschel

by Winnipeg Chapter Society for Neuroscience

Winnipeg Chapter Society for Neuroscience would like to recall the message, "Reminder: Friday - Dec 4th 9am - MNN Speaker - Dr. Chris Proschel".

8 years, 4 months

Reminder: Friday - Dec 4th **12noon** - MNN Speaker - Dr. Chris Proschel

by Winnipeg Chapter Society for Neuroscience

Please note lecture starts at 12noon. Manitoba Neuroscience Network 2015/2016 Seminar & Visiting Speaker Series Friday, December 4th, 2015 | 12:00 Noon Christoph J.W. Pröschel <https://www.urmc.rochester.edu/labs/proschel-lab/> Associate Professor of Genetics University of Rochester Medical Center, Department for Biomedical Genetics, Stem Cell and Regenerative Medicine Institute Pathways of Human Disease Program TOPIC: Glial cell therapy: the opportunity for restoring function by restoring tissue homeostasis. Location: Theatre C, Bannatyne Campus Within the context of our work on glial progenitor cells, we are now focusing on the role of astrocytes as critical modulators in response to injury or stress. The importance of understanding this process is emphasized by our discovery that the generation of mature astrocytes may be impaired in Vanishing White Matter leukodystrophy (Nat Med. 2005 Mar;11(3):277-83.). The ability to study astrocyte development in normal and pathological conditions, provides a unique opportunity to test the utility of glial precursor cells and their astrocytic progeny for cell transplantation therapy in diseases of the central nervous system (CNS), such as traumatic injury (spinal cord and traumatic brain injury) and neurodegenerative diseases (Parkinsons Disease, Multiple sclerosis). We have identified distinct astrocyte populations that demonstrate different functional properties with respect to their ability to promote injury repair upon transplantation into the injured nervous system. While one type shows little benefit and may even cause neuropathic pain syndrome, the other remodels the injured host tissue, enables axon outgrowth and extensive functional recovery (J Biol 2006 Apr 27, 5(3):7; J Biol 2008 Sep 19;7(7):245). As a prerequisite for the transition to the clinic we are analyzing the factors secreted by these astrocytes and have now derived homologous astrocyte populations from human precursor cells. (PLoS One. 2011 Mar 2;6(3)). For more information, contact the MNN Office at (T) 235.3939 or email: mnn(a)sbrc.ca

8 years, 4 months

Reminder: Friday - Dec 4th 9am - MNN Speaker - Dr. Chris Proschel

by Winnipeg Chapter Society for Neuroscience

Everyone is invited... Manitoba Neuroscience Network 2015/2016 Seminar & Visiting Speaker Series Friday, December 4th, 2015 | 12:00 Noon Christoph J.W. Pröschel <https://www.urmc.rochester.edu/labs/proschel-lab/> Associate Professor of Genetics University of Rochester Medical Center, Department for Biomedical Genetics, Stem Cell and Regenerative Medicine Institute Pathways of Human Disease Program TOPIC: Glial cell therapy: the opportunity for restoring function by restoring tissue homeostasis. Location: Theatre C, Bannatyne Campus Within the context of our work on glial progenitor cells, we are now focusing on the role of astrocytes as critical modulators in response to injury or stress. The importance of understanding this process is emphasized by our discovery that the generation of mature astrocytes may be impaired in Vanishing White Matter leukodystrophy (Nat Med. 2005 Mar;11(3):277-83.). The ability to study astrocyte development in normal and pathological conditions, provides a unique opportunity to test the utility of glial precursor cells and their astrocytic progeny for cell transplantation therapy in diseases of the central nervous system (CNS), such as traumatic injury (spinal cord and traumatic brain injury) and neurodegenerative diseases (Parkinsons Disease, Multiple sclerosis). We have identified distinct astrocyte populations that demonstrate different functional properties with respect to their ability to promote injury repair upon transplantation into the injured nervous system. While one type shows little benefit and may even cause neuropathic pain syndrome, the other remodels the injured host tissue, enables axon outgrowth and extensive functional recovery (J Biol 2006 Apr 27, 5(3):7; J Biol 2008 Sep 19;7(7):245). As a prerequisite for the transition to the clinic we are analyzing the factors secreted by these astrocytes and have now derived homologous astrocyte populations from human precursor cells. (PLoS One. 2011 Mar 2;6(3)). For more information, contact the MNN Office at (T) 235.3939 or email: mnn(a)sbrc.ca

8 years, 4 months

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

Neuro-All December 2015